<?xml version="1.0"?>
<trials subjects="1">
  <Triall>
    <main>
      <UTRN />
      <trial_id>ChiCTR1800014888</trial_id>
      <utrn />
      <reg_name>ChiCTR</reg_name>
      <date_registration>2018-02-12</date_registration>
      <primary_sponsor>The First Affiliated Hospital of Zhengzhou University</primary_sponsor>
      <public_title>Clinical observation of low-dose decitabine combined with valproic acid in allogeneic hematopoietic stem cell transplantation for hematologic malignancies</public_title>
      <acronym />
      <scientific_title>Clinical observation of low-dose decitabine combined with valproic acid in allogeneic hematopoietic stem cell transplantation for hematologic malignancies</scientific_title>
      <Scientific_acronym />
      <date_enrolment>2018-02-01</date_enrolment>
      <type_enrolment />
      <target_size>experimental group:50;control group:50;</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>http://www.chictr.org.cn/showproj.aspx?proj=25209</url>
      <study_type>Interventional study</study_type>
      <study_design>Randomized parallel controlled trial</study_design>
      <phase>Post-market</phase>
      <hc_freetext>hematologic malignancy</hc_freetext>
      <i_freetext>experimental group:low-dose decitabine combined with valproic acid;control group:nothing;</i_freetext>
      <results_actual_enrolment />
      <results_date_completed />
      <results_url_link />
      <results_summary />
      <results_date_posted />
      <results_date_first_publication />
      <results_baseline_char />
      <results_participant_flow />
      <results_adverse_events />
      <results_outcome_measures />
      <results_url_protocol />
      <results_IPD_plan />
      <results_IPD_description />
    </main>
    <contacts>
      <contact>
        <type>Scientific</type>
        <firstname>Guo Rong</firstname>
        <middlename />
        <lastname />
        <address>1 Jianshe Road East, Zhengzhou, He'nan, China </address>
        <city />
        <country1 />
        <zip />
        <telephone>+86 18203609539</telephone>
        <email>416054539@qq.com</email>
        <affiliation>The First Affiliated Hospital of Zhengzhou University</affiliation>
      </contact>
      <contact>
        <type>Public</type>
        <firstname>Guo Rong</firstname>
        <middlename />
        <lastname />
        <address>1 Jianshe Road East, Zhengzhou, He'nan, China </address>
        <city />
        <country1 />
        <zip />
        <telephone>+86 18860398705</telephone>
        <email>gh7311@aliyun.com</email>
        <affiliation>The First Affiliated Hospital of Zhengzhou University</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>China</country2>
    </countries>
    <criteria>
      <inclusion_criteria>(1) aged 14 to 60 years; 
(2) the diagnosis is in accordance with the guidelines formulated by the Chinese medical association's hematology division; 
(3) ECOG PS scores: 0 to 2; 
(4) the period of survival is estimated to be greater than 3 months;
(5) the subjects volunteered and signed informed consent forms, and signed informed consent procedures to meet the requirements of the quality management specification (GCP) of the pharmaceutical clinical trials.</inclusion_criteria>
      <agemin>14</agemin>
      <agemax>60</agemax>
      <gender>Both</gender>
      <exclusion_criteria>(1) the bone marrow cannot be absorbed through piercing; 
(2) diagnosing and merging other malignant tumors within 12 months prior to transplantation; 
(3) women in pregnancy or breastfeeding; 
(4)failing to control systemic fungi, bacteria or virus infection (defined as thetime of the symptoms/signs associated with infection, although the use of antibiotics or other treatment but still no improvement); 
(5) he is known or suspected to be allergic to the decitabine and valproic acid; 
(6) known human immunodeficiency virus (HIV) or the active stage virus infection of hepatitis b or c; 
(7) having a clear history of neurological or psychiatric disorders, including epilepsy or dementia; 
(8) according to the researchers' judgment, there is a serious riskof endangering the patient's safety, or the accompanying disease that affects the patient's completion of the research;
(9) other clinical trials of other drugs were taken prior to the use of other experimental drugs.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code />
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword />
    </health_condition_keyword>
    <intervention_code>
      <i_code>;;</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword />
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>myelogram;The occurrence of GVHD;</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Blood routine;</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name />
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id />
        <issuing_authority />
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>National Natural Science Foundation of China (81070445);2014 annual medical science and technology research project in henan province (201403029)</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Not approved</status>
        <approval_date>2013-08-26</approval_date>
        <contact_name />
        <contact_address />
        <contact_phone />
        <contact_email />
      </ethics_review>
    </ethics_reviews>
  </Triall>
</trials>